Metraipolis › archive › dc_f75b070e07ab
AI Innovation and Firm Performance in the Medical Device Industry — arXiv:2609.08485
- Source
- arXiv (en)
- Original
- https://arxiv.org/abs/2609.08485
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-16T13:38:30.313Z
- SHA-256 of the archived text
4dd5f3a1ff7ff83e86d7c9815438e08d39d4c87598e56d8105278bfd5dd8fb44- Stable URL of this page
https://metraipolis.com/documento/dc_f75b070e07ab
How to cite
AI Innovation and Firm Performance in the Medical Device Industry — arXiv:2609.08485 — arXiv (en), https://arxiv.org/abs/2609.08485 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_f75b070e07ab (Metraipolis archive dc_f75b070e07ab, sha256 4dd5f3a1ff7ff83e86d7c9815438e08d39d4c87598e56d8105278bfd5dd8fb44)
BibTeX
@misc{dcf75b070e07ab,
title = {AI Innovation and Firm Performance in the Medical Device Industry — arXiv:2609.08485},
howpublished = {arXiv (en)},
url = {https://arxiv.org/abs/2609.08485},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_f75b070e07ab; sha256 4dd5f3a1ff7ff83e86d7c9815438e08d39d4c87598e56d8105278bfd5dd8fb44},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: arXiv (en), https://arxiv.org/abs/2609.08485. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Whether artificial intelligence pays off for the firms that build it into their products is hard to establish, because AI innovation is itself hard to observe. The medical technology sector is a rare exception: an AI-enabled device must obtain clearance from a national health authority before it can reach a patient, leaving a dated, firm-attributable record of AI innovation output that can be observed directly rather than proxied. We exploit this setting with a three-stage recursive model estimated on a novel firm-level dataset linking FDA premarket clearances, USPTO patents, Scopus publications, and Orbis financials, tracing the full innovation chain from external collaboration through AI device introduction to firm performance. We find that external AI research collaboration is a robust driver of AI device introduction across firm sizes and estimators, with a larger effect for small firms, consistent with external knowledge ties substituting for limited internal R&D capacity. Decomposing by partner type, the effect is largest for industry and clinical collaborations and smallest for academic ties, consistent with the former being closer to the regulatory and commercialisation process. Firms that bring AI devices to market display higher labour productivity, an effect robust for small firms and the full sample that holds under both sequential and joint maximum-likelihood estimation and accumulates across successive device introductions. Effects on profit margins are present but weaker and do not survive all specifications, a pattern consistent with competitive entry eroding pricing power as AI devices diffuse through the sector. Tema degli esploratori: economia dei servizi IA (retro-catalogo arXiv: annunci del 2026-09-09 in econ.GN). Categorie arXiv: General Economics (econ.GN). Pagina del lavoro: https://arxiv.org/abs/2609.08485 — autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza: titolo e abstract sono metadati arXiv distribuiti in CC0 1.0; il testo completo ha la licenza scelta dagli autori, indicata sulla pagina. Letto il 2026-10-16T13:07:11.486Z dalla pagina https://arxiv.org/catchup/econ.GN/2026-09-09?abs=True (consentita dal robots.txt di arxiv.org, con il suo crawl-delay).